Abstract
BACKGROUND: Alzheimer disease (AD) is the most common cause of dementia worldwide. Despite the publication of numerous systematic reviews and meta-analyses that have summarized the evidence associated with pharmacotherapies (PTs) and non-pharmacotherapies (NPTs) for the wide range of interventions available for AD treatment, their comparative safety and efficacy remains insufficiently defined.
METHODS: Systematic reviews of randomized controlled trials (RCTs) will be selected according to the following criteria: conducted in elderly patients aged 60 years or older with AD living in community or institutionalized settings, applied pairwise meta-analysis (PMA) or network meta-analysis (NMA) approaches providing pooled relative treatment effects for at least 1 pair of PTs or NPTs, and providing at least 1 of the following outcomes for patients/caregivers: cognitive, functional status, behavior, quality of life (QoL), and caregiver stress or burden. All article screening, data extraction, and risk of bias assessment will be completed independently by 2 reviewers. Relative treatment rankings will be reported with mean ranks and surface under the cumulative ranking curves.
RESULTS AND CONCLUSION: We will determine the most efficacious treatment strategies for AD patients from the most highly ranked treatments. These results will help to guide clinical decision-making and improve patient care.
Original language | English |
---|---|
Article number | e32382 |
Number of pages | 6 |
Journal | Medicine |
Volume | 101 |
Issue number | 50 |
DOIs | |
Publication status | Published - 16 Dec 2022 |
Bibliographical note
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.Keywords
- Aged
- Humans
- Alzheimer Disease/drug therapy
- Systematic Reviews as Topic
- Meta-Analysis as Topic
- Treatment Outcome
- Network Meta-Analysis